Pharmaceuticals

A key driver of the Neutropenia Biologic Drug Treatment Market is the rising number of cardiovascular-related deaths linked to high LDL levels

March 23, 2026March 24, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Nexletol Market Evolve From 2026 To 2030?

Recent years have seen substantial growth in the nexletol market size. This market is projected to expand from $3.21 billion in 2025 to $3.65 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.8%. This historical growth can be ascribed to several factors, including the limited availability of cholesterol-lowering drug options, the high prevalence of hyperlipidemia, the widespread reliance on statin therapies, an increase in hospital and clinic prescriptions, and a rising awareness of cardiovascular risks.

The nexletol market is projected to experience swift expansion over the coming years. This market is anticipated to reach a valuation of $6.07 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.5%. Several factors will drive this growth during the forecast period, including the introduction of bempedoic acid-based therapies, the increased reach of medication delivery in homecare and long-term care settings, a rise in the occurrence of cardiovascular diseases, an intensifying focus on combination treatments, and the expanding healthcare infrastructure in emerging markets. Key trends anticipated during this period involve a growing acceptance of ldl-c lowering therapies, a shift towards oral administration rather than injectable forms, the proliferation of cardiovascular disease awareness initiatives, greater availability through both prescription and otc channels, and the integration of homecare and long-term care environments for medication utilization.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24621&type=smp

What Drivers Are Influencing The Nexletol Market?

The rising incidence of cardiovascular conditions is projected to drive the expansion of the nexletol market in the future. Cardiovascular diseases encompass various ailments impacting the heart and blood vessels, such as coronary artery disease, heart failure, and stroke. These diseases are escalating primarily because of more sedentary lifestyles; insufficient physical activity contributes to weight gain, metabolic irregularities, and elevated blood pressure, factors that substantially increase the risk of heart conditions. Nexletol offers advantages in managing cardiovascular diseases by reducing low-density lipoprotein (LDL) cholesterol levels, thereby assisting in diminishing arterial plaque accumulation and mitigating the likelihood of heart attacks and other related events. As an illustration, in January 2024, data from the American Heart Association, a US-based non-profit body, indicated that the age-adjusted mortality rate from cardiovascular disease rose to 233.3 per 100,000 in 2024, marking a 4.0% increase from 224.4 per 100,000 recorded in 2023. Consequently, the growing prevalence of cardiovascular diseases is set to stimulate the expansion of the nexletol market.

Which Segment Areas Are Covered In The Nexletol Market Analysis?

The nexletol market covered in this report is segmented –

1) By Type: 180mg, Other Types

2) By Administration Route: Oral, Injectable, Intravenous

3) By Indication: Hyperlipidemia, Atherosclerosis, Cardiovascular Disease

4) By End User: Hospitals, Clinics, Homecare Settings

Subsegments:

1) By 180 mg: Prescription-based, Over-The-Counter (OTC), Hospital or clinic use, Long-Term care facilities use

2) By Other Types: 40 mg, 80 mg, Other doses

What Key Developments And Trends Are Impacting The Nexletol Market?

Companies operating within the nexletol market are increasingly concentrating on the development of innovative oral non-statin therapies designed to lower LDL-cholesterol, such as bempedoic acid-based agents, to meet a rising demand driven by the limitations of existing statins. Bempedoic acid–based agents are oral medications that reduce cholesterol by inhibiting ATP citrate lyase (ACL), an enzyme involved in the liver’s pathway for cholesterol production, thereby decreasing LDL cholesterol; these agents support patients, particularly those who cannot tolerate statins, by lowering LDL-C through a liver-selective mechanism that avoids the muscle-related adverse effects often linked with traditional statins. For instance, in March 2024, Esperion Therapeutics, Inc., a U.S.-based biopharmaceutical company, received FDA approval for a significant label expansion for its drugs Nexletol (bempedoic acid) and Nexlizet (bempedoic acid + ezetimibe), allowing their use for both cardiovascular risk reduction and LDL-C lowering in primary and secondary prevention, regardless of whether patients are also using statins. Nexletol is an oral tablet taken once daily, formulated with bempedoic acid; it works by inhibiting ACL to reduce both LDL-C and inflammation, has shown reductions in major cardiovascular events during the CLEAR Outcomes trial, and provides a distinct, non-statin oral alternative with a favorable safety profile. The updated label substantially broadens patient eligibility across the U.S., which is set to strengthen its market adoption.

Which Global Companies Are Actively Competing In The Nexletol Market?

Major companies operating in the nexletol market are Esperion Therapeutics Inc., Daiichi Sankyo Company Limited, Otsuka Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Recordati S.p.A., Almirall S.A., Menarini Group, Les Laboratoires Servier, Torrent Pharmaceuticals Ltd., Lupin Limited, Zydus Lifesciences Limited, Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Limited, Cipla Limited, Aurobindo Pharma Limited, Intas Pharmaceuticals Limited, Glenmark Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Hetero Drugs Limited, Alkem Laboratories Limited, Wockhardt Limited, Mylan (Viatris Inc.), Teva Pharmaceutical Industries Limited, Apotex Inc., Hikma Pharmaceuticals PLC, Krka d.d., STADA Arzneimittel AG, Sandoz International GmbH

Read the full nexletol market report here:

https://www.thebusinessresearchcompany.com/report/nexletol-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Nexletol Market?

North America was the largest region in the nexletol market in 2025. The regions covered in the nexletol market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Nexletol Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24621&type=smp

Browse Through More Reports Similar to the Global Nexletol Market 2026, By The Business Research Company

Nematicides Market Report 2026

https://www.thebusinessresearchcompany.com/report/nematicides-global-market-report

Nebulizers Market Report 2026

https://www.thebusinessresearchcompany.com/report/nebulizers-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795